Cellular Mechanism of Action
The pharmacodynamics of Echinacea purpurea preparations is based on the sequential and comprehensive activation of the body's defense systems. Primarily, this affects the cellular branch of immunity, where the drug acts on several cell types simultaneously.
- Macrophage stimulation: The preparations significantly increase the phagocytic activity of macrophages. Cells of the monocyte-macrophage lineage more actively capture, engulf, and digest foreign antigens.
- Interleukin production: Under the influence of active substances in echinacea, macrophages sharply increase the production of interleukin-1 (IL-1). This critical mediator plays a key role in developing protective inflammatory responses and promotes the subsequent release of a cascade of other cytokines.
- Effect on granulocytes: A pronounced enhancement of granulocyte chemotaxis is observed. Consequently, leukocytes migrate faster and more purposefully from the bloodstream directly into the focus of inflammation.
Together, these cellular processes provide a powerful anti-inflammatory effect and increase the body's overall nonspecific resistance to infections.
Impact on Humoral Immunity and Hematopoiesis
In addition to marked cellular responses, echinacea-based herbal biogenic stimulants actively modulate humoral immunity and basic blood cell production processes.
- Bone marrow hematopoiesis: Echinacea directly stimulates hematopoiesis in the red bone marrow. The main clinical and laboratory manifestation of this pharmacodynamic effect is a predictable increase in the total leukocyte count in peripheral blood.
- T-helper activation: The preparations increase the functional activity of T-helper cells, which perform a regulatory function and are essential for launching a full humoral immune response.
- Antibody synthesis: A significant acceleration in the transformation of B-lymphocytes into mature plasma cells occurs. These plasmacytes are responsible for enhanced antibody production, ultimately reinforcing the body's ability to effectively resist pathogens.
Indications and Drug Representatives
In clinical practice, echinacea preparations are mainly used as adaptogens to correct weakened immunity. The pharmacological market features two main preparations with identical properties: Immunal (echinacea purpurea herb juice) and its analog Estifan (echinacea purpurea dry extract).
Main indications for use:
- Routine prophylaxis of common colds and seasonal influenza in at-risk patients.
- Combination therapy for secondary immunodeficiencies (marked weakening of immunity). Prescription is particularly relevant when immune suppression is caused by aggressive external factors or heavy treatments:
- Exposure to ionizing radiation or excessive ultraviolet (UV) irradiation.
- Undergoing toxic chemotherapy regimens.
- Prolonged and massive antibiotic therapy that depletes the patient's own protective reserves.
Strict Contraindications
Despite its status as an over-the-counter herbal adaptogen, echinacea is a potent immunostimulant. This makes its use strictly unacceptable in a number of severe systemic pathologies. Excessive stimulation of the immune system or hematopoiesis in these diseases can lead to fatal exacerbation.
Echinacea preparations are strictly contraindicated in:
- Tuberculosis: uncontrolled immune activation can unpredictably affect the course of specific granulomatous inflammation in the lungs and other organs.
- Leukemias: since echinacea stimulates bone marrow hematopoiesis and leukocyte proliferation, it can provoke rapid progression of the tumor clone in hemoblastoses.
- Collagenoses: in autoimmune connective tissue diseases, immune stimulation exacerbates damage to the body's own tissues.
- Multiple sclerosis: similar to collagenoses, stimulating T-helper activity and antibody production can repeatedly amplify the autoimmune attack on the myelin sheaths of nerve fibers.